DSX is a specialist life sciences advisory firm focused on commercial forecasting, portfolio strategy and strategic advisory.
We work with biotech and specialty pharma leadership teams on the decisions that matter most: indication prioritisation, portfolio choices, BD&L evaluation, launch planning, and the commercial assumptions that shape risk and value. The aim is not to produce more analysis for its own sake, but to help teams make clearer, more grounded decisions.
Leadership
DSX is led by Michael Hope, a senior pharmaceutical commercial analytics and strategy leader
With more than 20 years of experience across forecasting, portfolio strategy, pricing and access, rare disease commercialisation, global launch planning, and competitive analysis. That experience underpins a focused, senior-led approach built for leadership, governance and investment discussions.
The firm brings a practical international perspective, with experience across US, EU and UK commercial environments, including pricing and access systems, HTA-driven markets, rare disease pathways, and launch sequencing across regions.
DSX is not a generalist consultancy or a model outsourcing service. It is a focused advisory partner for leadership teams that need clearer commercial thinking, explicit assumptions and board-ready support around important decisions.
engagements
perspective
ready outputs
experience